Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDWD Stock Forecast 2025-2026
$19.43
Current Price
$213.78M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDWD Price Targets
+100.7%
To High Target of $39.00
+57.0%
To Median Target of $30.50
+28.7%
To Low Target of $25.00
MDWD Price Momentum
-4.8%
1 Week Change
-6.9%
1 Month Change
+42.4%
1 Year Change
+9.2%
Year-to-Date Change
-19.0%
From 52W High of $24.00
+52.0%
From 52W Low of $12.78
📊 TOP ANALYST CALLS
Did MDWD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MediWound is one of their latest high-conviction picks.
Latest MDWD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, MDWD has a bullish consensus with a median price target of $30.50 (ranging from $25.00 to $39.00). Currently trading at $19.43, the median forecast implies a 57.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Chase Knickerbocker at Craig-Hallum, projecting a 100.7% upside. Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 28.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDWD Analyst Ratings
6
Buy
0
Hold
0
Sell
MDWD Price Target Range
Low
$25.00
Average
$30.50
High
$39.00
Current: $19.43
Latest MDWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $31.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $25.00 |
| Feb 28, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $39.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $25.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $25.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| May 30, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Jan 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $28.00 |
| Nov 22, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $26.00 |
| Sep 21, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $26.00 |
| Aug 17, 2023 | Oppenheimer | Outperform | Maintains | $0.00 | |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 31, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
| May 31, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $63.00 |
| Mar 17, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
| Jan 4, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $23.00 |
| Dec 30, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $25.00 |
Mediwound Ltd. (MDWD) Competitors
The following stocks are similar to MediWound based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mediwound Ltd. (MDWD) Financial Data
Mediwound Ltd. has a market capitalization of $213.78M with a P/E ratio of -6.4x. The company generates $19.21M in trailing twelve-month revenue with a -110.5% profit margin.
Revenue growth is -20.3% quarter-over-quarter, while maintaining an operating margin of -132.1% and return on equity of -77.9%.
Valuation Metrics
Market Cap
$213.78M
Enterprise Value
$181.75M
P/E Ratio
-6.4x
PEG Ratio
-8.9x
Price/Sales
11.1x
Growth & Margins
Revenue Growth (YoY)
-20.3%
Gross Margin
+18.7%
Operating Margin
-132.1%
Net Margin
-110.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.2%
Current Ratio
2.2x
Debt/Equity
20.5x
ROE
-77.9%
ROA
-19.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mediwound Ltd. (MDWD) Business Model
About Mediwound Ltd.
What They Do
Develops therapeutics for wound care and tissue repair.
Business Model
Mediwound Ltd. generates revenue by developing, manufacturing, and commercializing innovative biopharmaceutical products, particularly focused on wound care solutions. The company primarily earns income through the sales of its enzymatic debridement agent and other therapeutic products designed to enhance healing outcomes in patients with various skin conditions.
Additional Information
Based in Israel, MediWound collaborates with international healthcare institutions and regulatory bodies, ensuring the effectiveness and accessibility of its products in global markets. The company's focus on improving patient care standards positions it well within the growing healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
111
CEO
Country
Israel
IPO Year
2014
Website
www.mediwound.comMediwound Ltd. (MDWD) Latest News & Analysis
Latest News
Quick Summary
MediWound Ltd. (NASDAQ:MDWD) will hold its Q1 2025 earnings conference call on May 21, 2025, at 8:30 AM ET, featuring key executives and analysts.
Why It Matters
MediWound's upcoming earnings call on May 21, 2025, will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
MediWound Ltd. reports Q1 revenue of $4M, reaffirming 2025 guidance at $24M. VALUE Phase III trial for EscharEx® and NexoBrid® manufacturing expansion are on track. Conference call today at 8:30 AM ET.
Why It Matters
MediWound's trial progress and manufacturing expansion signal growth potential. First quarter revenue and reaffirmed guidance indicate stability, influencing investor confidence in future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MediWound (MDWD) reported a quarterly loss of $0.07 per share, significantly better than the estimated loss of $0.65, and improved from a loss of $0.39 per share a year earlier.
Why It Matters
MediWound's smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MediWound is rated a buy, citing strong revenue growth, a promising pipeline, and solid financials, with NexoBrid's success and EscharEx's trial enhancing potential.
Why It Matters
MediWound's strong revenue growth, promising pipeline, and solid financial position suggest significant upside potential, making it an attractive investment opportunity amidst market uncertainties.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
A post hoc analysis in Wounds shows EscharEx® has superior clinical performance and a comparable safety profile to SANTYL®, indicating potential advantages for investors in related healthcare sectors.
Why It Matters
EscharEx® demonstrating superior clinical performance may boost its market share and revenue potential, impacting the valuation of related companies and influencing investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A conference call and webcast is set for May 21, 2025, at 8:30 a.m. ET. Investors should note this timing for potential updates or announcements.
Why It Matters
The scheduled conference call may provide critical updates on company performance and future guidance, impacting stock prices and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDWD Stock
What is Mediwound Ltd.'s (MDWD) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Mediwound Ltd. (MDWD) has a median price target of $30.50. The highest price target is $39.00 and the lowest is $25.00.
Is MDWD stock a good investment in 2025?
According to current analyst ratings, MDWD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDWD stock?
Wall Street analysts predict MDWD stock could reach $30.50 in the next 12 months. This represents a 57.0% increase from the current price of $19.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mediwound Ltd.'s business model?
Mediwound Ltd. generates revenue by developing, manufacturing, and commercializing innovative biopharmaceutical products, particularly focused on wound care solutions. The company primarily earns income through the sales of its enzymatic debridement agent and other therapeutic products designed to enhance healing outcomes in patients with various skin conditions.
What is the highest forecasted price for MDWD Mediwound Ltd.?
The highest price target for MDWD is $39.00 from Chase Knickerbocker at Craig-Hallum, which represents a 100.7% increase from the current price of $19.43.
What is the lowest forecasted price for MDWD Mediwound Ltd.?
The lowest price target for MDWD is $25.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 28.7% increase from the current price of $19.43.
What is the overall MDWD consensus from analysts for Mediwound Ltd.?
The overall analyst consensus for MDWD is bullish. Out of 10 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.50.
How accurate are MDWD stock price projections?
Stock price projections, including those for Mediwound Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:26 AM UTC